0EE0 trade ideas
$QURE Is A Hight Tight Flag - Here's How I Plan To Trade ItOf course I have no idea how the price of NASDAQ:QURE is going to open Monday morning, but if it opens within the body of Friday's candle or a little lower, I'll buy it two times as it breaks above 18.13 and then 18.50.
I'll set my stop to the low of the day and see what develops. Having moved up 150% in just 14 days it's an awfully powerful stock and deserves my attention here as it flags out with an acceptable 20% pullback.
I don't know what my position size is going to be on it yet. I have to wait and see where the low of the day is first and then decide how much capital to allocate. If risk is tight enough I'll get to full size buying one half above 18.13 and the second above 18.50.
I'll likely have to use limit buys here because it could move very quickly on me. Doing so means I risk not getting filled but it also means I don't end up taking on an uncomfortable amount of risk either.
Of course I drew my yellow line that I hope to see Monday off the chart and on the moon! Hopefully if that happens I'm well positioned.
We will see what Monday brings, but this is my number one priority at the opening bell.
Qure.NYSE Trend Cloud StudyuniQuire released some great Potential results from their latest Drugs Evaluation Results.
The markets responded positively. However soon retraced.
Was this just Hype?
The retracement is now down to the FIB 0.318 level.
The latest Market Analysts are showing a huge Upside Potential.
I Will be holding for now.
Your thoughts and Studies for future Upside or Downside is Appreciated.
As always, please get a few outside Expert's Advice before taking Trade or Investment Decisions.
Should you appreciate my Chart Studies, Smash That Rocket Boost Button. It's Just a Click away.
Regards Graham.
uniQure N.V - Positive divergenceOn the above 2-week chart uniQure N.V. price action has corrected 90% without the aid of share splits. A number of reasons now exist to consider a long position. They include:
1) Price action returns to legacy support.
2) RSI resistance breakout.
3) Strong positive divergence as measured over a 2-month period. Look left.
4) No share splits.
5) Price action previously topped out at the Fibonacci 1.414. Were that performance to repeat price action would top out at $215 with a 3600% return.
Is it possible price action continues to correct? Sure.
Is it probable? No.
Ww
Type: Investment
Risk: <6%
Timeframe for long: Qrt 1 2024
Stop loss: Will say elsewhere
$QURE - UniQure - Oversold and Indicator breakout. Target $30+Entry Price: $18.90
Stop Loss: $13.00
Take Profit: $25-$30 (=25% to +50%)
Technical Analysis
- Oversold on daily and weekly charts - low RSI and William %R
- Attempting a breakout above key MA's on the daily and retracing on the weekly.
- Formed a wedge/consolidated on the daily chart
- Key breakout on daily and weekly DMI
- Buy zone of $17-$20
- Target zones of $25-$30 (+25% to +50%)
Analyst Rating
- But with Target price $55
WATCH $QUREBullish
Fundamental
- High inflationary Macro environment / Market has no fear sentiment
- Funds Accumulation
- Positive PE
- Decent PEG
- Positive P/FCF
- Strong Sector / Industry
- Biotech seems to be breaking out
Technical
- Momentum Theory Indicator - bottomed and broke out neckline
- Price action formation ( falling wedge )
- Broke out Trend line with volume
- Price above 200MA
- Price above POC
- Broke ST
- Engulfing candle follow through
Entry idea
- For members
Stop loss depending on entry and risk appetite. But always set meaningful stops.
"the prize is in the process"
Cheers and happy trading!
QURE 2MuniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands
QURE Technical Analysis 🧙uniQure NV is a gene therapy company. It develops treatment and platform for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers-Squibb for cardiovascular diseases.
If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
Long QURE, found support and will climb after sell offQURE should continue climbing with recent sell off from news wall street did not like regarding licensing of their hemophilia drug. Support on Weekly MA found, MACD cross and RSI bullish divergence.
Phase 3 results should likely come out sometime in the future, like this quarter(?), based on company's prior reports.
Possible Short Setting UpThis pops out to me for a few reasons. Nice run this year. Net income a big negative, minus 83.3 mil. Have like 4 sell triggers/strat's on it already. Can see wave force up exhaustion. What's interesting is the near neckline support and then the gap. Just looks like its priming up to drop. Do your own due diligence. If x occurs do x1 if y occurs do Y1. Imagine different scenarios, take the one that confirms. They are a Gene Therapy play and do have some fast track designation for AMT-130 for treatment of Huntingtons disease. It is a hot sector. Could also be bought out. Probably going up on that hopium. Technically, could get interesting if those supports break. I'll be looking close if they break. If that was a five min intraday chart I'de be all over it scalping. Bio's are tricky, volatile. Caution. If I do get in this short I'll be scalping it down on a fast moving down support break. I don't like to hang around in these. To responsive to managed news. When it gets to these points of decision they are often pumped with news or something. Would be looking for that, but if they don't have any ammo it could get interesting.
QURE potential longQURE has been an extraordinarily strong performer since summer of last year, quintupling to $26+ a couple of weeks ago. The stock has since dropped a quick 20%. I plan to watch this tomorrow, and to buy on strength. My ultimate price target would be around $24, although I'd take first profit sooner. I like the fact that the company has a fair amount of cash in the bank, and no immediate need to dilute shareholders. But major catalysts are still a few months away, so I'd keep this on a short leash.